Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
|18/05/2020||Pause in Trading||Download|
|14/05/2020||Race starts preclinical breast cancer study for Bisantrene||Download|
|22/04/2020||Quarterly Activity Report & Appendix 4C||Download|
|23/03/2020||Notification of Lapse of Unlisted Options||Download|
|20/03/2020||Notification of Expiry of Unlisted Options||Download|
|18/03/2020||Phase II Bisantrene Trial Recruitment Completed||Download|
|12/03/2020||Appendix 2A-Completion of Placement||Download|